Literature DB >> 12923794

Cognitive-existential group psychotherapy for women with primary breast cancer: a randomised controlled trial.

David W Kissane1, Sidney Bloch, Graeme C Smith, Patricia Miach, David M Clarke, Jillian Ikin, Anthony Love, Nadia Ranieri, Dean McKenzie.   

Abstract

BACKGROUND: We conducted a randomised, controlled trial of cognitive-existential group therapy (CEGT) for women with early stage breast cancer receiving adjuvant chemotherapy with the aim of improving mood and mental attitude to cancer.
METHODS: Women were randomised to 20 sessions of weekly group therapy plus 3 relaxation classes or to a control arm receiving 3 relaxation classes. Assessments, independently done at baseline, 6 and 12 months, included a structured psychiatric interview and validated questionnaires covering mood, attitudes to cancer, family relationships, and satisfaction with therapy.
RESULTS: Three hundred and three of 491 (62%) eligible patients participated over 3 years. Distress was high pre-intervention: 10% were diagnosed as suffering from major depression, 27% from minor depression and 9% from anxiety disorders. On an intention-to-treat analysis, there was a trend for those receiving group therapy (n=154) to have reduced anxiety (p=0.05, 2-sided) compared to controls (n=149). Women in group therapy also showed a trend towards improved family functioning compared to controls (p=0.07, 2-sided). The women in the groups reported greater satisfaction with their therapy (p<0.001, 2-sided), appreciating the support and citing better coping, self-growth and increased knowledge about cancer and its treatment. They valued the CEGT therapy. Overall effect size for the group intervention was small (d=0.25), with cancer recurrence having a deleterious effect in three of the 19 therapy groups. Psychologists as a discipline achieved a moderate mean effect size (d=0.52).
CONCLUSION: CEGT is a useful adjuvant psychological therapy for women with early stage breast cancer. Interaction effects between group members and therapists are relevant to outcome. Group-as-a-whole effects are powerful, but the training and experience of the therapist is especially critical to an efficacious outcome. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2003        PMID: 12923794     DOI: 10.1002/pon.683

Source DB:  PubMed          Journal:  Psychooncology        ISSN: 1057-9249            Impact factor:   3.894


  60 in total

1.  Biobehavioral, immune, and health benefits following recurrence for psychological intervention participants.

Authors:  Barbara L Andersen; Lisa M Thornton; Charles L Shapiro; William B Farrar; Bethany L Mundy; Hae-Chung Yang; William E Carson
Journal:  Clin Cancer Res       Date:  2010-06-08       Impact factor: 12.531

2.  Longitudinal Reciprocal Relationships Between Quality of Life and Coping Strategies Among Women with Breast Cancer.

Authors:  Min-So Paek; Edward H Ip; Beverly Levine; Nancy E Avis
Journal:  Ann Behav Med       Date:  2016-10

3.  Pilot randomized controlled trial of individual meaning-centered psychotherapy for patients with advanced cancer.

Authors:  William Breitbart; Shannon Poppito; Barry Rosenfeld; Andrew J Vickers; Yuelin Li; Jennifer Abbey; Megan Olden; Hayley Pessin; Wendy Lichtenthal; Daniel Sjoberg; Barrie R Cassileth
Journal:  J Clin Oncol       Date:  2012-02-27       Impact factor: 44.544

4.  Reduction of cancer-specific thought intrusions and anxiety symptoms with a stress management intervention among women undergoing treatment for breast cancer.

Authors:  Michael H Antoni; Sarah R Wimberly; Suzanne C Lechner; Aisha Kazi; Tammy Sifre; Kenya R Urcuyo; Kristin Phillips; Roselyn G Smith; Vida M Petronis; Sophie Guellati; Kurrie A Wells; Bonnie Blomberg; Charles S Carver
Journal:  Am J Psychiatry       Date:  2006-10       Impact factor: 18.112

Review 5.  A review and recommendations for optimal outcome measures of anxiety, depression and general distress in studies evaluating psychosocial interventions for English-speaking adults with heterogeneous cancer diagnoses.

Authors:  Tim Luckett; Phyllis N Butow; Madeleine T King; Mayumi Oguchi; Gaynor Heading; Nadine A Hackl; Nicole Rankin; Melanie A Price
Journal:  Support Care Cancer       Date:  2010-07-02       Impact factor: 3.603

6.  Addressing fear of cancer recurrence among women with cancer: a feasibility and preliminary outcome study.

Authors:  Sophie Lebel; Christine Maheu; Monique Lefebvre; Scott Secord; Christine Courbasson; Mina Singh; Lynne Jolicoeur; Aronela Benea; Cheryl Harris; Michael Fung Kee Fung; Zeev Rosberger; Pamela Catton
Journal:  J Cancer Surviv       Date:  2014-04-23       Impact factor: 4.442

7.  Individual meaning-centered psychotherapy for the treatment of psychological and existential distress: A randomized controlled trial in patients with advanced cancer.

Authors:  William Breitbart; Hayley Pessin; Barry Rosenfeld; Allison J Applebaum; Wendy G Lichtenthal; Yuelin Li; Rebecca M Saracino; Allison M Marziliano; Melissa Masterson; Kristen Tobias; Natalie Fenn
Journal:  Cancer       Date:  2018-05-14       Impact factor: 6.860

8.  Meaning-centered group psychotherapy: an effective intervention for improving psychological well-being in patients with advanced cancer.

Authors:  William Breitbart; Barry Rosenfeld; Hayley Pessin; Allison Applebaum; Julia Kulikowski; Wendy G Lichtenthal
Journal:  J Clin Oncol       Date:  2015-02-02       Impact factor: 44.544

9.  Meaning-centered group psychotherapy for patients with advanced cancer: a pilot randomized controlled trial.

Authors:  William Breitbart; Barry Rosenfeld; Christopher Gibson; Hayley Pessin; Shannon Poppito; Christian Nelson; Alexis Tomarken; Anne Kosinski Timm; Amy Berg; Colleen Jacobson; Brooke Sorger; Jennifer Abbey; Megan Olden
Journal:  Psychooncology       Date:  2010-01       Impact factor: 3.894

10.  Making sense of caregiving for persons with multiple sclerosis (MS): the dimensional structure of sense making and relations with positive and negative adjustment.

Authors:  Kenneth I Pakenham
Journal:  Int J Behav Med       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.